Days before Endo International filed for Chapter 11 protection, the pharmaceutical company, which is mired in opioid epidemic-related litigation, quietly doled out “excessive and inappropriate” bonuses to the firm’s executives, including its top lawyer. 

That’s according to a recent filing with the U.S. Bankruptcy Court for the Southern District of New York, where a committee of seven attorneys general and a bankruptcy trustee argued that Endo has attempted to “escape accountability and enrich its executives” through millions in “secret” bonuses.